The Supreme Court’s intervention follows a restrictive ruling from the US Court of Appeals for the 5th Circuit, which had moved to block federal rules allowing the drug to be distributed via mail. Drugmakers quickly appealed to the high court, prompting Alito to issue a temporary stay that keeps current distribution protocols in place while the justices continue their review.
Democratic lawmakers and reproductive health organizations remain critical of the ongoing legal volatility. Senate Minority Leader Chuck Schumer described the order as a reminder that essential healthcare remains under constant threat, while Senator Patty Murray emphasized that medical decisions should rely on scientific evidence rather than the interventions of extremist judges. The legal friction traces back to early 2023, when the FDA permanently lifted in-person dispensing requirements, a policy change that triggered a lawsuit from Louisiana officials.
Rachel Fey, interim co-CEO of Power to Decide, noted that the current uncertainty forces patients and providers to operate in a state of flux, deepening the existing barriers to care. Legal analysts suggest the court’s ultimate direction remains unclear; the Associated Press highlighted that the current dispute mirrors a 2020 case that the court eventually dismissed due to a lack of legal standing. Meanwhile, the Department of Justice has requested that lower courts pause litigation to allow the FDA to finalize a safety review of the medication, which has been in use since 2000.
Comments (0)
No comments yet. Be the first!